
Longwood creates and invests in science-based companies that develop novel solutions for important medical problems.
Location: United States, Massachusetts, Boston
Employees: 1-10
Founded date: 2010
Investment Type: Venture Capital
Portfolio 1
Date | Name | Website | Total Raised | Location |
24.06.2022 | DEM Biopha... | dembiopharma.com | $70M | United Sta... |
Mentions in press and media 21
Date | Title | Description |
15.02.2025 | Newleos Therapeutics: A New Dawn in Neuropsychiatric Treatment | In the world of mental health, the need for innovation is as urgent as a fire alarm. Newleos Therapeutics has stepped into this arena with a bold vision and a hefty $93.5 million in Series A funding. This clinical-stage neuroscience company... |
14.02.2025 | Newleos Therapeutics: $93.5 Million (Series A) Raised For Transforming Treatment Of Neuropsychiatric Disorders | Newleos Therapeutics—a clinical-stage neuroscience company co-founded by Longwood Fund and seasoned leaders in CNS drug development—announced the closing of an oversubscribed $93.5 million Series A financing. Goldman Sachs Alternatives led ... |
13.02.2025 | Newleos Therapeutics Debuts with $93.5 Million Oversubscribed Series A Financing to Transform the Treatment of Neuropsychiatric Disorders through the Advancement of Novel Medicines | -Newleos aims to develop first-in-class and best-in-class therapies to address the need for safer and more efficacious treatment options for major mental health conditions- -Multiple clinical-stage programs licensed from Roche, ready for pr... |
15.01.2025 | Be Bio Closes $92M Series C Financing | Be Bio, a Cambridge, MA-based company which specializes in B Cell Medicines (BCMs), raised $92M in Series C funding. The round was led by Nextech with existing investors including ARCH Venture Partners, Atlas Venture, RA Capital Management,... |
09.11.2024 | Evommune Secures $115 Million to Tackle Chronic Inflammatory Diseases | In the bustling world of biotechnology, Evommune has made waves. The Palo Alto-based company recently secured $115 million in Series C financing. This funding is a lifeline, aimed at advancing their clinical-stage pipeline focused on immune... |
08.11.2024 | Evommune: $115 Million (Series C) Secured To Advance Clinical-Stage Pipeline Addressing Chronic Inflammatory Diseases | Evommune – a clinical-stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases – announced the completion of a $115 million Series C financing. The funding was co-led by new investors RA... |
28.10.2024 | Be Biopharma: Pioneering the Future of Genetic Medicine with $82 Million in New Funding | In the ever-evolving landscape of biotechnology, Be Biopharma stands out like a lighthouse in a storm. This Cambridge, Massachusetts-based company has just secured $82 million in funding, a financial windfall that promises to propel its inn... |
25.10.2024 | Be Bio: $82 Million Raised To Discover And Develop Engineered B Cell Medicines | Be Biopharma – a leader in the discovery and development of engineered B Cell Medicines (BCMs) – announced key milestones alongside a new round of funding as its lead program BE-101 for Hemophilia B, enters the clinic, and its second develo... |
03.04.2024 | From generative chemistry to computational astrophysics, startups employ new methods to fight cancer | Here are a few startups in the cancer space that made headlines recently The recent revelation of Princess Kate Middleton’s battle with cancer has sent ripples across the globe, reminding us that this disease knows no boundaries of status o... |
19.03.2024 | Engrail Therapeutics raises $157M Series B | Engrail Therapeutics, a precision neuroscience company focused on the development of transformational therapies to improve the lives of patients, today announced that it has closed an oversubscribed $157 million Series B financing round. Th... |
Show more